Cantor Fitzgerald Raises Price Target on Bristol-Myers Squibb to $50 From $45
Cantor Fitzgerald Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $885
Zoetis Price Target Announced at $220.00/Share by BTIG
Zoetis Analyst Ratings
BTIG Initiates Zoetis(ZTS.US) With Buy Rating, Announces Target Price $220
Eli Lilly and Co Analyst Ratings
Wolfe Research Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,117
Wolfe Research Adjusts Eli Lilly's Price Target to $1,117 From $909
Buy Rating Affirmed: Sangamo's Hemophilia A Gene Therapy Poised for Success With Pfizer Partnership
Piper Sandler Maintains Viatris(VTRS.US) With Hold Rating, Maintains Target Price $13
Jefferies Maintains Zoetis(ZTS.US) With Buy Rating, Cuts Target Price to $200
Buy Rating Affirmed for Zoetis Amidst Favorable Market Dynamics and Strong Growth Potential
Hold Rating on Bristol-Myers Squibb Amid Mixed Performance and Evolving Pipeline
Deutsche Numis Initiates Bristol-Myers Squibb(BMY.US) With Hold Rating, Announces Target Price $45
Johnson & Johnson Analyst Ratings
Daiwa Downgrades Johnson & Johnson to Neutral From Outperform, Adjusts Price Target to $150 From $160
Bristol-Myers Squibb Analyst Ratings
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Guggenheim Adjusts Johnson & Johnson's Price Target to $156 From $160, Maintains Neutral Rating
Intra-Cellular Therapies Analyst Ratings